Pivagabine Explained
Pivagabine (INN; brand name Tonerg), also known as N-pivaloyl-γ-aminobutyric acid or N-pivaloyl-GABA, is an antidepressant and anxiolytic drug which was introduced in Italy in 1997 for the treatment of depressive and maladaptive syndromes. But it was discontinued in Italy (according to Martindale). Originally believed to function as a prodrug to GABA,[1] pivagabine is now believed to act somehow via modulation of corticotropin-releasing factor (CRF).[2] [3] [4] [5] [6]
See also
Notes and References
- Bianchi M, Quadro G, Mourier G, Galzigna L . Pharmacokinetics and in vitro effects of a 4-aminobutyric acid derivative with anticonvulsant action . Pharmacology . 27 . 4 . 237–40 . 1983 . 6634934 . 10.1159/000137876.
- Scapagnini U, Matera M . Effects of pivagabine on psychophysical performance and behavioural response in experimental models of stress . Arzneimittel-Forschung . 47 . 11A . 1310–4 . November 1997 . 9450154 .
- Esposito G, Luparini MR . Pivagabine: a novel psychoactive drug . Arzneimittelforschung. 47 . 11A . 1306–9 . November 1997 . 9450153 .
- Gerra G, Zaimovic A, Giusti F, etal . Pivagabine effects on neuroendocrine responses to experimentally-induced psychological stress in humans . Behavioural Brain Research . 122 . 1 . 93–101 . July 2001 . 11287080 . 10.1016/S0166-4328(01)00177-2. 23067609 .
- Serra M, Concas A, Mostallino MC, etal . Antagonism by pivagabine of stress-induced changes in GABAA receptor function and corticotropin-releasing factor concentrations in rat brain . Psychoneuroendocrinology . 24 . 3 . 269–84 . April 1999 . 10101733 . 10.1016/S0306-4530(98)00049-3. 11382166 .
- Book: George I. Papakostas. Maurizio Fava. Pharmacotherapy for Depression and Treatment-resistant Depression. 2010. World Scientific. 978-981-4287-59-3. 370–.
